Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H17N7O6.2Na |
| Molecular Weight | 485.3611 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].NC1=NC2=C(N=C(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=N2)C(=O)N1
InChI
InChIKey=SWIRFWUEJODNRG-LTCKWSDVSA-L
InChI=1S/C19H19N7O6.2Na/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28;;/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30);;/q;2*+1/p-2/t12-;;/m0../s1
DescriptionCurator's Comment: description was created based on several sources, including
http://pubs.acs.org/doi/abs/10.1021/ja01853a512 | https://www.ncbi.nlm.nih.gov/pubmed/28031963 | https://www.ncbi.nlm.nih.gov/pubmed/1560436
Curator's Comment: description was created based on several sources, including
http://pubs.acs.org/doi/abs/10.1021/ja01853a512 | https://www.ncbi.nlm.nih.gov/pubmed/28031963 | https://www.ncbi.nlm.nih.gov/pubmed/1560436
Folic Acid is a B complex vitamin containing a pteridine moiety linked by a methylene bridge to para-aminobenzoic acid, which is joined by a peptide linkage to glutamic acid. Conjugates of Folic Acid are present in a wide variety of foods, particularly liver, kidneys, yeast and leafy green vegetables. Commercially available Folic Acid is prepared synthetically. Folic Acid occurs as a yellow or yellowish-orange crystalline powder and is very slightly soluble in water and insoluble in alcohol. Aqueous solutions of Folic Acid are heat sensitive and rapidly decompose in the presence of light and/or riboflavin; solutions should be stored in a cool place protected from light. Folic Acid is effective in the treatment of megaloblastic anemias due to a deficiency of Folic Acid (as may be seen in tropical or nontropical sprue) and in anemia of nutritional origin, pregnancy, infancy, or childhood. Folic Acid is relatively nontoxic in man. Rare instances of allergic responses to Folic Acid preparations have been reported and have included erythema, skin rash, itching, general malaise, and respiratory difficulty due to bronchospasm. Endocyte is developing an intravenous (IV) formulation of folic acid, called Neocepri®, which is intended for the diagnosis of positive folate receptor-positive status in patients with ovarian cancer when administered prior to the radioactive medicine, technetium Tc99m Etarfolatide. The benefits of Neocepri® are its ability to reduce the background activity observed on single photon emission computed tomography (SPECT) imaging in most normal, nontarget tissues (e.g. intestines, liver, kidney, spleen), thereby improving the image quality of the scans. The product had been granted orphan drug designation in the EU. Endocyte had filed a conditional marketing authorization application (CMA) with the European Medicines Agency (EMA) for Neocepri®.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0006760 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | FOLVITE Approved UseIndications and Usage. Folic Acid is effective in the treatment of megaloblastic anemias due to a deficiency of Folic Acid (as may be seen in tropical or nontropical sprue) and in anemia of nutritional origin, pregnancy, infancy, or childhood. Launch Date1947 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
25.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18551467/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
FOLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
76 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18551467/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
FOLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.93 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18551467/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
FOLIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
3 mg 1 times / day steady, oral (min) Highest studied dose Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, adult n = 480526 Health Status: healthy Condition: pregnant Age Group: adult Sex: F Population Size: 480526 Sources: |
Other AEs: Autism spectrum disorder... |
400 ug 1 times / day steady, oral Recommended Dose: 400 ug, 1 times / day Route: oral Route: steady Dose: 400 ug, 1 times / day Sources: |
healthy, adult n = 1257 Health Status: healthy Condition: pregnant Age Group: adult Sex: F Population Size: 1257 Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Autism spectrum disorder | 6.8% | 3 mg 1 times / day steady, oral (min) Highest studied dose Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, adult n = 480526 Health Status: healthy Condition: pregnant Age Group: adult Sex: F Population Size: 480526 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Folic acid-induced acute renal failure in the the rat: morphological studies. | 1976 Oct |
|
| Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-91. | 1994 Nov 14 |
|
| [Reduced number of neural tube defects after folic acid supplementation in China]. | 1999 Dec 1 |
|
| Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. | 1999 Jun |
|
| Modulation of fluorouracil antitumor activity by folic acid in a murine model system. | 1999 Sep 1 |
|
| Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. | 2000 |
|
| [Sulphur amino acids, vitamin B12 and folic acid in children with chronic renal failure]. | 2000 Apr |
|
| Folic acid antagonists during pregnancy and the risk of birth defects. | 2000 Nov 30 |
|
| Up-regulation of galectin-3 in acute renal failure of the rat. | 2000 Sep |
|
| Conversion of 5-formyltetrahydrofolic acid to 5-methyltetrahydrofolic acid is unimpaired in folate-adequate persons homozygous for the C677T mutation in the methylenetetrahydrofolate reductase gene. | 2000 Sep |
|
| Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. | 2001 |
|
| Rationale for risk reduction of cardiovascular disease using homocysteine concentration in blood and plasma as biomarker: support by clinical data. | 2001 |
|
| A bifunctional dihydrofolate synthetase--folylpolyglutamate synthetase in Plasmodium falciparum identified by functional complementation in yeast and bacteria. | 2001 Feb |
|
| Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. | 2001 Feb |
|
| Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design. | 2001 Feb |
|
| Intake of vegetables rich in carotenoids and risk of coronary heart disease in men: The Physicians' Health Study. | 2001 Feb |
|
| Lowered weight gain during pregnancy and risk of neural tube defects among offspring. | 2001 Feb |
|
| Homocysteine, its metabolites, and B-group vitamins in renal transplant patients. | 2001 Feb |
|
| Recent insights into the molecular genetics of the homocysteine metabolism. | 2001 Feb |
|
| Homocysteine metabolism in renal failure. | 2001 Feb |
|
| The folate cycle and disease in humans. | 2001 Feb |
|
| Methylenetetrahydrofolate reductase genotypes and predisposition to atherothrombotic disease; evidence that all three MTHFR C677T genotypes confer different levels of risk. | 2001 Feb |
|
| Selected food intake and risk of multiple pregnancies. | 2001 Feb |
|
| C677T variant form at the MTHFR gene and CL/P: a risk factor for mothers? | 2001 Feb 1 |
|
| It's just a vitamin.. | 2001 Feb 1 |
|
| Lack of clinical utility of folate levels in the evaluation of macrocytosis or anemia. | 2001 Feb 1 |
|
| Bioactivity of [6R]-5-formyltetrahydrofolate, an unusual isomer, in humans and Enterococcus hirae, and cytochrome c oxidation of 10-formytetrahydrofolate to 10-formyldihydrofolate. | 2001 Feb 15 |
|
| [Homocysteine, endothelial dysfunction and cardiovascular risk: pathomechanisms and therapeutic options]. | 2001 Jan |
|
| Preconceptual folic acid: opportunity for preconceptual counseling offers opportunity to help prevent neural tube defects. | 2001 Jan |
|
| Characterization of three genes encoding enzymes of the folate biosynthetic pathway in Plasmodium falciparum. | 2001 Jan |
|
| Nitrous oxide-induced cobalamin deficiency. | 2001 Jan |
|
| Gastric tube graft interposition as an oesophageal substitute. | 2001 Jan |
|
| Lp(a) lipoprotein--an independent risk factor for coronary heart disease after menopause. | 2001 Jan |
|
| Vitamin B12 deficiency in children and adolescents. | 2001 Jan |
|
| Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. | 2001 Jan |
|
| Maternal plasma homocysteine levels in women with preterm premature rupture of membranes. | 2001 Jan |
|
| Diagnosis and treatment of hyperhomocysteinemia. | 2001 Jan |
|
| Multivitamins, folate, and colon cancer. | 2001 Jan |
|
| Hyperhomocysteinaemia in young adults is not associated with impaired endothelial function. | 2001 Jan |
|
| Retroviral expression of Escherichia coli thymidylate synthase cDNA confers high-level antifolate resistance to hematopoietic cells. | 2001 Jan 1 |
|
| Comparison of the bacterial flora of the duodenum in healthy cats and cats with signs of gastrointestinal tract disease. | 2001 Jan 1 |
|
| Factors that influence the penetration of methotrexate through solid tissue. | 2001 Jan 1 |
|
| Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. | 2001 Jan 12 |
|
| Diet-induced hyperhomocysteinemia exacerbates neointima formation in rat carotid arteries after balloon injury. | 2001 Jan 2 |
|
| Synthesis and evaluation of pteroic acid-conjugated nitroheterocyclic phosphoramidates as folate receptor-targeted alkylating agents. | 2001 Jan 4 |
|
| [Folates, vitamin B12, homocysteine and neural tube defects]. | 2001 Jan-Feb |
|
| Antisense modulation of 5,10-methylenetetrahydrofolate reductase expression produces neural tube defects in mouse embryos. | 2001 Jan-Feb |
|
| Human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/inosine 5'-monophosphate cyclohydrolase. A bifunctional protein requiring dimerization for transformylase activity but not for cyclohydrolase activity. | 2001 Mar 16 |
|
| The basal promoters for the human reduced folate carrier gene are regulated by a GC-box and a cAMP-response element/AP-1-like element. Basis for tissue-specific gene expression. | 2001 Mar 2 |
|
| Repression of human reduced folate carrier gene expression by wild type p53. | 2001 Mar 23 |
Patents
Sample Use Guides
Usual Adult Dose for Megaloblastic Anemia: 1 mg orally, intramuscularly, subcutaneously or IV once a day.
Nutritional Supplementation (Recommended daily allowance): Males: 400 mkg/day, Females: 400-800 mkg/day, Pregnant women: 600 mkg/day, Nursing women: 500 mkg/day, Upper limit: 1 mg/day.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
0E65X9XZ7Y
Created by
admin on Sat Dec 16 10:36:58 GMT 2023 , Edited by admin on Sat Dec 16 10:36:58 GMT 2023
|
PRIMARY | |||
|
101744084
Created by
admin on Sat Dec 16 10:36:58 GMT 2023 , Edited by admin on Sat Dec 16 10:36:58 GMT 2023
|
PRIMARY | |||
|
29704-76-5
Created by
admin on Sat Dec 16 10:36:58 GMT 2023 , Edited by admin on Sat Dec 16 10:36:58 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
